Clinical Trials · NCT00171873
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Carmen Schade-Brittinger
- Enrollment
- 85
- Start date
- Sep 2001
- Locations
- 10 sites, Germany
- Primary endpoint
- Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)